Welcome Guest
Home » Reports » 3D Bioprinting: Technologies, Products and Key Application Areas, (2nd Edition), 2018-2035

3D Bioprinting: Technologies, Products and Key Application Areas, (2nd Edition), 2018-2035

Published: Nov 20, 2017
Pages: 350
Product Code: RA10095
License Type :  (Learn More)

3D printing has garnered significant attention within the healthcare industry. The concept of 3D bioprinting was conceived in the late 1990s; since then, various industry stakeholders and academicians have undertaken several initiatives in order to further develop / improve this technology for a variety of applications. Organovo was the first company to enter the 3D bioprinting space by printing functional blood vessels in 2010. The company now offers 3D printed kidney and liver tissue models. There have been a number of other notable attempts to create fully functional 3D bioprinted tissues. For instance, in 2015, 3D Bioprinting Solutions became the first company to print and transplant a thyroid gland in a mouse. Subsequently, in the same year, Aspect Biosystems developed and commercialized 3D printed human respiratory tissue for clinical testing. In addition to these, other companies with commercialized tissue products include MEDPRIN, Poietis, and Sirris.

 

The current applications of 3D bioprinted products cater to various requirements within the pharmaceutical industry for clinical testing of therapeutic drugs. Owing to the evident interspecies differences, drug candidates that are shown to be efficacious in animal models often fail in humans. For such purposes, 3D bioprinting can be used to develop more accurate, human specific disease models. Further, there is a severe unmet need when it comes to organ transplants. Therefore, the ability to synthetically create organs for transplantation purposes is expected to generate a lot of interest amongst pharmaceutical / biotechnology players in the coming years.

 

The current market landscape of 3D bioprinting is characterized by the presence of nearly equal number of industry and non-industry players, featuring a number of startups and university spin-offs. Although there are several 3D bioprinting technologies already available, active efforts are being made to add to the intellectual property portfolio. The field has witnessed growing partnering activity and has also managed to capture the interest of both public and private sector investors.Despite certain challenges, several technical advancements and high unmet need of current patients waiting for organ transplants is anticipated to significantly drive future growth.

 

  • Synopsis
  • Table of
    Contents
  • List of
    Figures
  • List of
    Tables
  • Listed Companies
  • Sample
    Pages
  • Download Brochure

The 3D Bioprinting: Technologies, Products and Key Application Areas, (2nd Edition), 2018-2035’ report provides a comprehensive study on the current market landscape of the 3D bioprinting industry, featuring an elaborate discussion on the future potential of this evolving market. The field has seen the emergence of many new players in the past few years; in fact, several well-known players of the 3D printing industry have broadened their focus to launch new initiatives specific to 3D bioprinting. Amongst other things, the report features:

  • A detailed overview of the current market landscape of 3D bioprinters and 3D bioprinted products, highlighting the contributions of industry and non-industry players, including information on the various technological aspects and key specifications of such technologies / products.
  • Profiles of developers of bioprinting devices / technologies and bioprinted products. Each profile includes an overview of the company, information on their financials (wherever available), details on their respective product portfolios, 3D bioprinting specific collaborations, and an informed future outlook.
  • A comprehensive product competitiveness analysis of existing 3D bioprinters, based on supplier power and product specific features such as type of technology and range of applications.
  • An analysis of the partnerships that have been established in the recent past, covering research agreements, distribution agreements, product development agreements and other relevant deals, along with information on the collaborators / partners.
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies that are focused in this area.
  • An analysis depicting the prevalent and emerging trends in 3D bioprinting as observed on the social media platform, Twitter. The report also includes a detailed case study on the upcoming trends, such as use of stem cells as bioinks, emergence of the concept of 4D bioprinting and commercialization of low-cost bioprinters, based on inputs from primary and secondary research.
  • An analysis of intellectual property portfolio related to 3D bioprinting. The study presents a high-level view on the granted patents and submitted patent applications related to these technologies, highlighting the prevalent trends in this domain. In addition, the analysis highlights the most active geographies and the key players driving innovation in this field.

 

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as target consumer segments, expected adoption rates and pricing, we have provided an informed estimate of the likely evolution of the opportunity within the market in the short to mid-term and long term, for the period 2018-2035. To account for the uncertainties associated with the development of 3D bioprinted products and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

 

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The study includes detailed transcripts of discussions held with Douglas Chrisey (Professor, Tulane University), Fanny Geraldo and Lisa Oliver (Researchers, University of Nantes), Glauco R. Souza (President and Chief Scientific Officer, n3D Biosciences), Igor Zlatkin (Application Scientist, Digilab), Kenneth Church (President and Chief Executive Officer, nScrypt) and Xudong Chen (Executive Vice President Business Development & Sales, nScrypt), Laura Bosworth (Chief Executive Officer and Co-founder, TeVido BioDevices), Lauralyn McDaniel (Industry Manager, SME), Marc Thurner (Chief Executive Officer, regenHU), Roger Narayan (Professor, North Carolina State University) and Simon Fried (Chief Business Officer, Nano Dimension). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

 

 

Example Highlights

  1. Over 70 bioprinters are currently either commercialized or under development; of these, close to 75% have been developed by industry players. Examples of commercialized 3D bioprinters by industry stakeholders include (in alphabetical order) 3D-Bioplotter® Series (EnvisionTEC), 3D Discovery® Series (regenHU), ALPHA-CP™ (SunP Biotech), Allevi 6 / BioBot 2 (Allevi / BioBots), BIO X (CELLINK), Fab@Home M4™ (Seraph Robotics) and Jetlab® 4-Larger Area (MicroFab Technologies).
  2. Overall, more than 100 players, from both industry and academia, are currently focused on the development of 3D bioprinters and 3D bioprinted products. It is worth noting that several start-ups have emerged in the past five years; recent examples (in alphabetical order) include CELLINK, Flexadyne, Precise Bio, REGEMAT 3D, and Symme 3D. A significant proportion of startups are university spin-offs, including 3Dynamic Systems (Swansea University), Allevi (University of Pennsylvania), Aspect Biosystems (University of Columbia), Oxford MEStar (Oxford University) and Poietis (University of Bordeaux).
  3. Around 60 research institutions are currently active in this field. In fact, close to 30% of the players are focused on developing their own 3D bioprinters; examples include (in alphabetical order), ClemsonUniversity, Heriot-Watt University, Ludwig Maximilian University of Munich (LMU), Medical University of South Carolina (MUSC), Nanyang Technological University (NTU), Technical University of Munich (TUM), University of Toronto, University of Wollongong and Wake Forest Baptist Medical Center.
  4. Over 60% of the available bioprinters are based on the extrusion technology; examples include (in alphabetical order) ALPHA (3Dynamic Systems), Bio3D SYN^ (Bio3D Technologies), Bioscaffolder 3.1 (GeSim), Regenovo Bio-Printer (Regenovo Biotechnology) and UN-BIO-MINI / MINI Bio-printer (Qingdao Unique Products Develop). This is followed by inkjet-based bioprinters and laser-based bioprinters, which presently represent 26% and 2% of the total number of bioprinters, respectively. Apart from these, other types of technologies used in bioprinters include Kenzan technology, synQuad technology, piezoelectric nanoelectric pipetting and freeze-drying deposition mechanisms.
  5. Several players are actively engaged in attempts to come up with new and innovative bioprinting techniques. This activity can be observed in the increasing number of patent applications filed related to 3D bioprinting. Of the total number of patents filed / granted from 1992 to late 2017, over 85% of the patents were filed in the last five years, beginning 2013.The US and China have emerged as global leaders in terms of intellectual property; these regions currently contribute to 37% and 27% of the filed patents, respectively.
  6. The number of partnerships established annually over the past five years demonstrate an increasing trend; we identified close to 65 partnerships inked during the period 2012-2017. Majority of these partnerships are focused on R&D activities related to bioprinting technologies and products. Examples of recent research agreements include collaborations between Aether and University of South Australia (UniSA) (August 2017), GeSim and BellaSeno (August 2017), Trideo and Foundation for the Fight Against Infantile Neurological Diseases (FLENI) (May 2017), Symme3D and Center for Gene and Cellular Therapies in the Treatment of Cancer (OncoGen) (April 2017), and Aspect Biosystems and University of Manitoba (March 2017).
  7. A variety of interesting trends, such as the development of bioinks in ready to print formats (by companies such as CELLINK) and introduction of the concept of 4D bioprinting (by companies such as Poietis), are emerging. In addition, several companies, for instance, Allevi (BioBots), BioCurious, Ourobotics, Seraph Robotics and SunP Biotech International, have undertaken efforts to develop low cost bioprinters. Multiple initiatives have also been launched to modify the existing 3D bioprinting techniques and come up with scaffold-free bioprinters.
  8. As different products get approved for a diverse range of applications within the pharmaceutical / biotechnology market, we expect the market to witness a series of growth spurts across different applications, such as drug testing / drug screening, tissue engineering / tissue implants and organ transplants, in the coming years. Overall, we expect the 3D bioprinted products market to grow at an annualized rate of over 64% between 2018 and 2035.
  9. Specifically, 3D printed organs for transplantation are expected to drive the long-term growth in this field; by 2035, we are led to believe that such organs have the potential to contribute to around 25% of the market’s share by 2035.  North America and Europe are likely to maintain their dominance over the next decade. However, emerging regions, such as China, are expected to grow at a relatively faster rate as compared to the developed regions.

 

 

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

 

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

 

While the focus has been on forecasting the market till 2030, the report also provides our view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

 

 

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the 3D bioprinting market in the mid to long term.

 

Chapter 3 provides a general overview of 3D bioprinting, covering its historical background, evolution and current applications. In addition, the section provides information on the material and technical requirements, and the process of bioprinting.

 

Chapter 4 provides a comprehensive market landscape of 3D bioprinters and bioprinted products that have already been developed and / or are under development. This chapter includes information on the developers, applications, technologies, details on different printing parameters (for instance, cell viability, precision, print speed and resolution) and the cost of bioprinters. 

 

Chapter 5 presents profiles of some of the active players (based on the number of bioprinters / commercialized bioprinted products) in this domain, highlighting their expertise related to 3D bioprinters and bioprinted products. Each profile provides a brief overview of the company, 3D bioprinting devices and / or bioprinted products, its financial information (wherever available), recent developments and a comprehensive future outlook.

 

Chapter 6 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst stakeholders in this market. The chapter includes details on the different partnership models, such as research agreements, distribution agreements, product development agreements and licensing agreements that have been established in the period between 2012 and late 2017. In addition, we have presented details on the various investments and grants received by companies between 2012 to late 2017, highlighting the growing interest of the venture capital community and other strategic investors within this market.

 

Chapter 7 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of 3D bioprinting, under a comprehensive SWOT framework.

 

Chapter 8 provides insights on the popularity of 3D bioprinting on the social media platform, Twitter. The section features an analysis of the yearly distribution of tweets posted on the platform in the time period 2012 to late 2017, highlighting the most significant events responsible for the increase / decrease in the volume of tweets each year.

 

Chapter 9 provides insights on recent trends in the 3D bioprinting industry, such as scaffold-free printing, stem cell based bioinks, 4D bioprinting and advent of low-cost bioprinters, which are expected to influence the adoption of bioprinted products in the coming years.

 

Chapter 10 features a comparison of product competitiveness and supplier power of bioprinters in the form of a 2 x 2 matrix. The analysis takes into considerations several parameters such as type of technology and range of applications offered by these bioprinters.

 

Chapter 11 provides a detailed analysis of the patents that have been filed in the field of 3D bioprinting. The analysis highlights emerging trends in the intellectual property portfolio of this field, and identifies the key players that are driving innovation in this space.

 

Chapter 12 presents a comprehensive market forecast analysis, highlighting the future potential of 3D bioprinting, till the year 2035. We have segregated the opportunity on the basis of the type of application of the bioprinted product (drug testing / drug screening, tissue engineering / tissue implants and organ transplant), type of bioprinting technology (extrusion, inkjet, laser and others) and the geographical distribution of the market (North America, Europe, Asia Pacific and Rest of the World). The sales potential and future growth opportunity were estimated based on the target patient population, likely adoption rates and the likely price of products.

 

Chapter 13 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

 

Chapter 14 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of discussions held with the following individuals:

  1. Douglas Chrisey (Professor, Tulane University)
  2. Fanny Geraldo and Lisa Oliver (Researchers, University of Nantes)
  3. Glauco R. Souza (President and Chief Scientific Officer, n3D Biosciences)
  4. Igor Zlatkin (Application Scientist, Digilab)
  5. Kenneth Church (President and Chief Executive Officer, nScrypt) and Xudong Chen (Executive Vice President Business Development & Sales, nScrypt)
  6. Laura Bosworth (Chief Executive Officer and Co-founder, TeVido BioDevices)
  7. Lauralyn McDaniel (Industry Manager, SME)
  8. Marc Thurner (Chief Executive Officer, regenHU)
  9. Roger Narayan (Professor, North Carolina State University)
  10. Simon Fried (Chief Business Officer, Nano Dimension)

 

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

 

Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.

 

 
1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. Executive Summary
 
3. Introduction
3.1. Chapter Overview
3.2. 3D Printing Technology
3.2.1. Overview
3.2.2. Historical Evolution
3.2.3. 3D Printing in Medicine
3.3. 3D Bioprinting: Printing of Living Cells, Tissues and Organs
3.3.1. Historical Evolution
3.3.2. Process and Requirements
3.3.3. 3D Bioprinting Applications
3.3.3.1. Toxicity Screening / Drug Testing
3.3.3.2. Tissue Engineering
3.3.3.3. Organ Replacement 
 
4. Market Landscape
4.1. Chapter Overview
4.2. 3D Bioprinting: Overall Market Landscape
4.2.1. 3D Bioprinters by Industry Players
4.2.1.1. Distribution by Geographical Location of Developers
4.2.1.2. Distribution by Founding Year of Developers
4.2.1.3. Distribution by Applications
4.2.1.4. Distribution by Cost of 3D Bioprinters
4.2.1.5. Distribution by Technology of 3D Bioprinters
4.2.1.6. Physical Features of 3D Bioprinters 
4.2.1.7. Printing Parameters of 3D bioprinters
 
4.2.2. 3D Bioprinted Products by Industry Players
4.2.2.1. Distribution by Geographical Location of Developers
4.2.2.2. Distribution by Type of Product
 
4.3. 3D Bioprinters by Non-Industry Players
4.3.1. Distribution by Geographical Location of Developers
4.3.2. Distribution by Development Status
 
4.4. 3D Bioprinted Products by Non-Industry Players
4.4.1. Distribution by Geographical Location of Academia
4.4.2. Distribution by Type of Product
4.4.3. Distribution by Development Status
 
5. Company Profiles
5.1. Chapter Overview
5.2. 3Dynamic Systems
5.2.1. Company Overview
5.2.2. Product Portfolio
5.2.2.1. 3DS Alpha Bioprinter 
5.2.2.2. 3DS Omega Bioprinter
5.2.2.3. Gel4Cell®
5.2.3. Recent Developments
5.2.4. Future Outlook
 
5.3. Aspect Biosystems
5.3.1. Company Overview
5.3.2. Product Portfolio
5.3.2.1. 3DAirwayALI™
5.3.2.2. 3DBioRing Airway™
5.3.2.3. RX1™
5.3.3. Awards and Accomplishments
5.3.4. Recent Developments
5.3.5. Future Outlook
 
5.4. Allevi (formerly BioBots)  
5.4.1. Company Overview
5.4.2. Product Portfolio
5.4.2.1. Allevi 2 (BioBot 1)
5.4.2.2. Allevi 6 (BioBot 2)
5.4.3. Awards and Accomplishments
5.4.4. Future Outlook
 
5.5. BioDan Group
5.5.1. Company Overview
5.5.1.1. BioDan SkinMed
5.5.1.2. BioDan Sciences
5.5.1.3. BioDan Print
5.5.2. Recent Developments
5.5.3. Future Outlook
 
5.6. CELLINK
5.6.1. Company Overview
5.6.2. Product Portfolio
5.6.2.1. INKREDIBLE 3D Bioprinter
5.6.2.2. INKREDIBLE+ 3D Bioprinter
5.6.2.3. BIO X
5.6.2.4. Bioinks
5.6.3. Awards and Accomplishments
5.6.4. Recent Developments
5.6.5. Future Outlook
 
5.7. EnvisionTEC
5.7.1. Company Overview
5.7.2. Product Portfolio
5.7.2.1. 3D-Bioplotter® Starter Series
5.7.2.2. 3D-Bioplotter® Developer Series
5.7.2.3. 3D-Bioplotter® Manufacturer Series
5.7.3. Awards and Accomplishments
5.7.4. Recent Developments
5.7.5. Future Outlook
 
5.8. GeSiM
5.8.1. Company Overview
5.8.2. Product Portfolio
5.8.2.1. Bioscafolder 3.1 (BS3.1)
5.8.3. Recent Developments
5.8.4. Future Outlook
 
5.9. MEDPRIN BIOTECH
5.9.1. Company Overview
5.9.2. Product Portfolio
5.9.2.1. ReDura™
5.9.2.2. NeoDura™
5.9.3. Recent Developments
5.9.4. Future Outlook
 
5.10. microdrop Technologies
5.10.1. Company Overview
5.10.2. Product Portfolio
5.10.2.1. Autodrop Compact System
5.10.2.2. Autodrop Professional Positioning System AD-P-8000
5.10.3. Recent Developments
5.10.4. Future Outlook
 
5.11. MicroFab Technologies
5.11.1. Company Overview
5.11.2. Product Portfolio
5.11.2.1. JetLab® 4 Printing Platforms
5.11.2.2. JetLab® II-Precision
5.11.3. Awards and Accomplishments
5.11.4. Recent Developments
5.11.5. Future Outlook
 
5.12. Nano3D Biosciences
5.12.1. Company Overview
5.12.2. Product Portfolio
5.12.2.1. Magnetic 3D Bioprinting Technology
5.12.3. Recent Developments
5.12.4. Future Outlook
 
5.13. Organovo
5.13.1. Company Overview
5.13.2. Product Portfolio
5.13.2.1. NovoGen MMX™
5.13.2.2. ExVive™ 3D Bioprinted Human Liver Tissues
5.13.2.3. ExVive™ 3D Bioprinted Human Kidney Tissues
5.13.3. Preclinical Study Results
5.13.4. Awards and Accomplishments
5.13.5. Recent Developments
5.13.6. Future Outlook
 
5.14. Qingdao Unique Products Develop
5.14.1. Company Overview
5.14.2. Product Portfolio
5.14.2.1. 3D Bio-Printer
5.14.2.2. Anyprint B01CS
5.14.2.3. Bio-Membrane Printer
5.14.2.4. MINI Bio–Printer
5.14.2.5. Re-human
5.14.3. Recent Developments
5.14.4. Future Outlook
 
5.15. regenHU
5.15.1. Company Overview
5.15.2. Product Portfolio
5.15.2.1. 3D Discovery™
5.15.2.2. BioFactory™
5.15.2.3. OsteoInk™
5.15.2.4. Stark™
5.15.3. Awards and Accomplishments
5.15.4. Recent Developments
5.15.5. Future Outlook
 
5.16. SunP Biotech International
5.16.1. Company Overview
5.16.2. Product Portfolio
5.16.2.1. ALPHA-CP™ 21
5.16.2.2. ALPHA-BP™ 11
5.16.2.3. APLHA-CP™ 41
5.16.3. Future Outlook
 
6. Recent Collaborations and Funding
6.1. Chapter Overview
6.2. Partnership Models 
6.3. 3D Bioprinting: Recent Collaborations
6.3.1. Analysis by Year of Collaborations 
6.3.2. Analysis by Type of Collaborations 
6.3.3. Most Active Companies: Analysis by Number of Collaborations 
 
6.4. Venture Capital Interest
6.5. Types of Funding
6.6. 3D Bioprinting: Funding Instances
6.6.1. Analysis by Type of Funding Instance
6.6.2. Analysis by Number of Funding Instances
 
7. SWOT Analysis
7.1. Chapter Overview
7.2. Strengths
7.3. Weaknesses
7.4. Opportunities
7.5. Threats
 
8. Emerging Trends on Social Media
8.1. Chapter Overview
8.2. Trends on Twitter
8.3. Popular Keywords and Word Cloud Analysis
 
9. Recent Trends in 3D Bioprinting Industry
9.1. Chapter Overview
9.2 Introduction of Scaffold-Free Bioprinting
9.3 Emergence of 4D Bioprinting: the Next Generation of 3D Bioprinting
9.4 Use of Stem Cells as Bio Ink
9.5 Development of UV 3D Bioprinting, a Modified Stereolithography Approach
9.6 Establishment of Spin-Offs of Academic Institutes
9.7 Entry of Well-Established Players of 3D Printing Industry in Bioprinting Industry 
9.8 Introduction of Low-Priced Bioprinters
9.9 Increasing Number of Initiatives Taken by Governments of Different Countries
 
10. Product Competitiveness Analysis
10.1. Chapter Overview
10.2. Scope and Methodology
10.3 3D Bioprinters: 2 x 2 Product Competitiveness vs. Supplier Power Analysis
 
11. Patent Analysis
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. 3D Bioprinting Patents: Distribution by Publication Year
11.4. 3D Bioprinting Patents: Distribution by Geographical Location
11.5. 3D Bioprinting Patents: Distribution by CPC Classifications
11.6. 3D Bioprinting Patents: Emerging Areas
11.7. 3D Bioprinting Patents: Leading Players
 
12. Market Forecast and Opportunity Analysis
12.1. Chapter Overview
12.2. Forecast Methodology
12.3. Overall 3D Bioprinting Market, 2018-2035
12.4. 3D Bioprinting Market: Distribution by Applications
12.4.1. 3D Bioprinting Market for Drug Testing / Drug Screening
12.4.2. 3D Bioprinting Market for Tissue Engineering / Tissue Implants 
12.4.2.1. 3D Bioprinted Skin
12.4.2.2. 3D Bioprinted Cornea
12.4.2.3. 3D Bioprinted Cartilage
12.4.2.4. 3D Bioprinted Bone 
12.4.2.5. 3D Bioprinted Blood Vessels
12.4.2.6. 3D Bioprinted Heart Valves
 
12.4.3. 3D Bioprinting Market for Organ Transplants 
12.4.3.1. 3D Bioprinted Breast Implants 
12.4.3.2. 3D Bioprinted Kidney
12.4.3.3. 3D Bioprinted Liver
12.4.3.4. 3D Bioprinted Heart
 
12.5. 3D Bioprinting Market: Distribution by Region (North America, Europe, Asia Pacific and Rest of the World)
12.6. 3D Bioprinting Market: Distribution by Technology (Extrusion, Inkjet, Laser and Others)
 
13. Conclusion
13.1. 3D Bioprinting has Garnered Significant Attention within the Biopharmaceutical Industry
13.2. The Competitive Market Landscape Features a Mix of Industry and Non-Industry Players
13.3. North America and Europe Dominate the Current Market; Several Companies based in the Asia Pacific are also Making Notable Progress
13.4. Research Continues to be the Major Focus as Stakeholders Strive to Improve Existing Methods and Technologies
13.5. Increasing Partnership Activity and Financial Support from Public and Private Investors are Expected to Drive Growth
13.6. Recent Advances are Expected to Act as Catalyst to the Success of 3D Bioprinting
13.7. Inherent Challenges Must be Overcome to Tap the Multi-billion Dollar Opportunity in the Long Term
 
14. Interview Transcripts
14.1. Chapter Overview
14.2. Douglas Chrisey, Professor, Tulane University 
14.3. Igor Zlatkin, Application Scientist and Chirantan Kanani, Technology & Product Development, Digilab 
14.4. Fanny Geraldo and Lisa Oliver, Researchers, University of Nantes 
14.5. Glauco R Souza, President & Chief Scientific Officer and Hubert Tseng, Senior Research Scientist, n3D Biosciences 
14.6. Kenneth Church, President & Chief Executive Officer and Xudong Chen, Executive Vice President Business Development & Sales, nScrypt
14.7. Laura Bosworth, Chief Executive Officer & Co-Founder, TeVido BioDevices
14.8. Lauralyn McDaniel, Industrial Manager, SME
14.9. Marc Thurner, Chief Executive Officer, regenHU
14.10. Roger Narayan, Professor, North Carolina State University 
14.11. Simon Fried, Chief Business Officer, Nano Dimension
14.12. Anonymous, MicroFab Technologies
 
15. Appendix 1: Tabulated Data
16. Appendix 2: List of Companies and Organizations
 
 
Figure 3.1 The Bioprinting Process
 
Figure 4.1 3D Bioprinters by Industry Players: Distribution by Geographical Location of Developers
 
Figure 4.2 3D Bioprinters by Industry Players: Distribution by Founding Year of Developers
 
Figure 4.3 3D Bioprinters by Industry Players: Distribution by Applications
 
Figure 4.4 3D Bioprinters by Industry Players: Distribution by Cost (USD)
 
Figure 4.5 3D Bioprinters by Industry Players: Distribution by Technology
 
Figure 4.6 3D Bioprinters by Industry Players: Distribution by Printer Weight 
 
Figure 4.7 3D Bioprinters by Industry Players: Distribution by Number of Printheads
 
Figure 4.8 3D Bioprinted Products by Industry Players: Distribution by Geographical Location of Developers
 
Figure 4.9 3D Bioprinted Products by Industry Players: Distribution by Product Type
 
Figure 4.10 3D Bioprinters by Non-Industry Players: Distribution by Geographical Location of Academia
 
Figure 4.11 3D Bioprinters by Non-Industry Players: Distribution by Development Status
 
Figure 4.12 3D Bioprinted Products by Non-Industry Players: Distribution by Geographical Location of Academia
 
Figure 4.13 3D Bioprinted Products by Non-Industry Players: Distribution by Product Type
 
Figure 4.14 3D Bioprinted Products by Non-Industry Players: Distribution by Development Status
 
Figure 5.1 Organovo: Annual Revenues, 2011- 2017 (USD Million)
 
Figure 6.1 3D Bioprinting Collaborations: Distribution by Year, 2012-2017
 
Figure 6.2 3D Bioprinting Collaborations: Distribution by Type of Model, 2012-2017
 
Figure 6.3 3D Bioprinting Collaborations: Most Active Players, 2012-2017
 
Figure 6.4 3D Bioprinting Funding Instances: Distribution by Type of Funding, 2012-2017
 
Figure 6.5 3D Bioprinting Funding Instances: Distribution by Total Amount Invested, 2012-2017 (USD Million)
 
Figure 6.6 3D Bioprinting Funding Instances: Most Active Players, 2012-2017
 
Figure 7.1 3D Bioprinting: SWOT Analysis
 
Figure 7.2 3D Bioprinting SWOT Analysis: Strengths
 
Figure 7.3 3D Bioprinting SWOT Analysis: Weaknesses
 
Figure 7.4 3D Bioprinting SWOT Analysis: Opportunities
 
Figure 7.5 3D Bioprinting SWOT Analysis: Threats 
 
Figure 8.1 3D Bioprinting Social Media Analysis: Yearly Distribution of Tweets, January 2012-September 2017
 
Figure 8.2 3D Bioprinting Social Media Analysis: Popular Keywords on Twitter, January 2012 to September 2017
 
Figure 10.1 3D Bioprinters: Product Competitiveness Analysis
 
Figure 11.1 3D Bioprinting Patents: Distribution by Publication Type
 
Figure 11.2 3D Bioprinting Patents: Distribution by Publication Year
 
Figure 11.3 3D Bioprinting Patents: Distribution by Year and Regions
 
Figure 11.4 3D Bioprinting Patents: Distribution by CPC Classification Symbol
 
Figure 11.5 3D Bioprinting Patents: Emerging Areas
 
Figure 11.6 3D Bioprinting Patents: Leading Assignees
 
Figure 11.7 3D Bioprinting Patents: Geographical Distribution of Leading Assignees
 
Figure 12.1 3D Bioprinting Market: Short-Mid Term (2018-2027), Base Scenario (USD Billion)
 
Figure 12.2 3D Bioprinting Market: Mid-Long Term (2027-2035), Base Scenario (USD Billion)
 
Figure 12.3 3D Bioprinting Market: Distribution by Applications 2020, 2029 and 2035, Base Scenario (USD Billion)
 
Figure 12.4 3D Bioprinting Market for Drug Testing / Drug Screening: Short-Mid Term (2018-2027), Base Scenario (USD Billion)
 
Figure 12.5 3D Bioprinting Market for Drug Testing / Drug Screening: Mid-Long Term (2027-2035), Base Scenario (USD Billion)
 
Figure 12.6 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Short-Mid Term (2018-2027), Base Scenario (USD Billion)
 
Figure 12.7 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Mid-Long Term (2027-2035), Base Scenario (USD Billion)
 
Figure 12.8 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Distribution by Tissue Type, 2025, 2030 and 2035, Base Scenario (USD Billion)
 
Figure 12.9 3D Bioprinting Market for Bioprinted Skin: Short-Mid Term (Till 2027), Base Scenario (USD Billion)
 
Figure 12.10 3D Bioprinting Market for Bioprinted Skin: Mid-Long Term, (Till 2035), Base Scenario (USD Billion)
 
Figure 12.11 3D Bioprinting Market for Bioprinted Cornea: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
 
Figure 12.12 3D Bioprinting Market for Bioprinted Cartilage: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
 
Figure 12.13 3D Bioprinting Market for Bioprinted Bone: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
 
Figure 12.14 3D Bioprinting Market for Bioprinted Blood Vessels: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
 
Figure 12.15 3D Bioprinting Market for Bioprinted Heart Valves: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
 
Figure 12.16 3D Bioprinting Market for Organ Transplants: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
 
Figure 12.17 3D Bioprinting Market for Bioprinted Breast Implants: Long Term (Till 2035), Base Scenario (USD Billion)
 
Figure 12.18 3D Bioprinting Market for Bioprinted Kidney: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
 
Figure 12.19 3D Bioprinting Market for Bioprinted Liver: Long Term (Till 2035), Base Scenario (USD Billion)
 
Figure 12.20 3D Bioprinting Market for Bioprinted Heart: Long Term (Till 2035), Base Scenario (USD Billion)
 
Figure 12.21 3D Bioprinting Market: Distribution by Region, (Till 2035), Base Scenario (USD Billion)
 
Figure 12.22 3D Bioprinting Market: Distribution by Technology, (Till 2035), Base Scenario (USD Billion)
 
Figure 13.1 3D Bioprinting Market: Key Drivers
 
Figure 13.2 3D Bioprinting Market: 2018, 2027 and 2035 (USD Billion)
 
 
Table 3.1 RepRap Project: 3D Printing Machines
 
Table 3.2 Inputs for 3D Bioprinting
 
Table 4.1 List of 3D Bioprinters by Industry Players
 
Table 4.2 3D Bioprinters by Industry Players: Bioprinting Technologies
 
Table 4.3 3D Bioprinters by Industry Players: Physical Features
 
Table 4.4 3D Bioprinters by Industry Players: Printing Parameters
 
Table 4.5 List of 3D Bioprinted Products by Industry Players
 
Table 4.6 List of 3D Bioprinters by Non-Industry Players
 
Table 4.7 List of 3D Bioprinted Products by Non-Industry Players
 
Table 5.1 3Dynamic Systems: Product Portfolio
 
Table 5.2 3Dynamic Systems: Technical Specifications of 3DS Alpha
 
Table 5.3 3Dynamic Systems: Technical Specifications of 3DS Omega
 
Table 5.4 Aspect Biosystems: Product Portfolio 
 
Table 5.5 Aspect Biosystems: Technical Specifications of RX1™
 
Table 5.6 BioBots: Product Portfolio
 
Table 5.7 Allevi (BioBots): Technical Specifications of Allevi 2 (BioBot 1)
 
Table 5.8 Allevi (BioBots): Technical Specifications of Allevi 6 (BioBot 2)
 
Table 5.9 BioDan Group: Therapeutic Segments
 
Table 5.10 CELLINK: Product Portfolio
 
Table 5.11 CELLINK: Technical Specifications of INKREDIBLE 3D Bioprinter
 
Table 5.12 CELLINK: Technical Specifications of INKREDIBLE+ 3D Bioprinter
 
Table 5.13 CELLINK: Technical Specifications of BIO X
 
Table 5.14 CELLINK: Specifications of Bioinks
 
Table 5.15 EnvisionTEC: Product Portfolio
 
Table 5.16 EnvisionTEC: Consumables for 3D-Bioplotter® Bioprinters
 
Table 5.17 EnvisionTEC: Technical Specifications of 3D-Bioplotter® Starter Series
 
Table 5.18 EnvisionTEC: Technical Specifications of 3D-Bioplotter® Developer Series
 
Table 5.19 EnvisionTEC: Technical Specifications of 3D-Bioplotter® Manufacturer Series
 
Table 5.20 GeSiM: Product Portfolio
 
Table 5.21 GeSiM: Technical Specifications of BioScaffolder3.1
 
Table 5.22 MEDPRIN BIOTECH: Product Portfolio
 
Table 5.23 MEDPRIN BIOTECH: Technical Specifications of ReDura™
 
Table 5.24 microdrop Technologies: Product Portfolio
 
Table 5.25 microdrop Technologies: Technical Specifications of Autodrop Compact System
 
Table 5.26 microdrop Technologies: Technical Specifications of Autodrop Professional Positioning System AD-P-8000
 
Table 5.27 MicroFab Technologies: Product Portfolio
 
Table 5.28 MicroFab Technologies: Technical Specifications of JetLab®4
 
Table 5.29 MicroFab Technologies: Technical Specifications of JetLab® II-Precision
 
Table 5.30 n3D Biosciences: Product Portfolio
 
Table 5.31 Organovo: Product Portfolio 
 
Table 5.32 Qingdao Unique Products Develop: Product Portfolio
 
Table 5.33 Qingdao Unique Products Develop: Technical Specifications of 3D Bio-Printer
 
Table 5.34 Qingdao Unique Products Develop: Technical Specifications of Anyprint B01CS
 
Table 5.35 Qingdao Unique Products Develop: Technical Specifications of Bio-Membrane Printer
 
Table 5.36 Qingdao Unique Products Develop: Technical Specifications of MINI Bio-Printer
 
Table 5.37 regenHU: Product Portfolio
 
Table 5.38 regenHU: Technical Specifications of 3D Discovery™
 
Table 5.39 regenHU: Technical Specifications of BioFactory™
 
Table 5.40 regenHU: Types and Details of ECM-BioInks™
 
Table 5.41 regenHU: Technical Specifications of OsteoInk™
 
Table 5.42 SunP Biotech International: Product Portfolio
 
Table 5.43 SunP Biotech International: Technical Specifications of ALPHA-CP™ 21
 
Table 5.44 SunP Biotech International: Technical Specifications of APLHA-BP™ 11
 
Table 5.45 SunP Biotech International: Technical Specifications of APLHA-CP™ 41
 
Table 6.1 3D Bioprinting: Recent Collaborations, 2012-2017
 
Table 6.2 3D Bioprinting: List of Funding Instances and Investors, 2012-2017 
 
Table 6.3 3D Bioprinting: Types of Funding Instances, 2012-2017
 
Table 11.1 3D Bioprinting Patents: CPC Symbol Definitions
 
Table 11.2 3D Bioprinting Patents: Most Popular CPC Symbols
 
Table 11.3 3D Bioprinting Patents: List of Top CPC Classifications
 
Table 12.1 Expected Launch Timeline of 3D Bioprinted Products for Different Applications 
 
Table 15.1 3D Bioprinters by Industry Players: Distribution by Geographical Location of Developers
 
Table 15.2 3D Bioprinters by Industry Players: Distribution by Founding Year of Developers
 
Table 15.3 3D Bioprinters by Industry Players: Distribution by Applications
 
Table 15.4 3D Bioprinters by Industry Players: Distribution by Cost (USD)
 
Table 15.5 3D Bioprinters by Industry Players: Distribution by Technology
 
Table 15.6 3D Bioprinters by Industry Players: Distribution by Printer Weight 
 
Table 15.7 3D Bioprinters by Industry Players: Distribution by Number of Printheads
 
Table 15.8 3D Bioprinted Products by Industry Players: Distribution by Geographical Location of Developers
 
Table 15.9 3D Bioprinted Products by Industry Players: Distribution by Product Type
 
Table 15.10 3D Bioprinters by Non-Industry Players: Distribution by Geographical Location of Academia
 
Table 15.11 3D Bioprinters by Non-Industry Players: Distribution by Development Status
 
Table 15.12 3D Bioprinted Products by Non-Industry Players: Distribution by Geographical Location of Academia
 
Table 15.13 3D Bioprinted Products by Non-Industry Players: Distribution by Product Type
 
Table 15.14 3D Bioprinted Products by Non-Industry Players: Distribution by Development Status
 
Table 15.15 Organovo: Annual Revenues, 2011- 2017 (USD Million)
 
Table 15.16 3D Bioprinting Collaborations: Distribution by Year, 2012-2017
 
Table 15.17 3D Bioprinting Collaborations: Distribution by Type of Model, 2012-2017
 
Table 15.18 3D Bioprinting Collaborations: Most Active Players, 2012-2017
 
Table 15.19 3D Bioprinting Funding Instances: Distribution by Type of Funding, 2012-2017
 
Table 15.20 3D Bioprinting Funding Instances: Distribution by Total Amount Invested, 2012-2017 (USD Million)
 
Table 15.21 3D Bioprinting Funding Instances: Most Active Players, 2012-2017
 
Table 15.22 3D Bioprinting Patents: Distribution by Publication Type
 
Table 15.23 3D Bioprinting Patents: Distribution by Publication Year
 
Table 15.24 3D Bioprinting Patents: Distribution by Year and Regions
 
Table 15.25 3D Bioprinting Patents: Leading Assignees
 
Table 15.26 3D Bioprinting Patents: Geographical Distribution of Leading Assignees
 
Table 15.27 3D Bioprinting Market: Short-Mid Term (2018-2027), Conservative Scenario (USD Billion)
 
Table 15.28 3D Bioprinting Market: Short-Mid Term (2018-2027), Base Scenario (USD Billion)
 
Table 15.29 3D Bioprinting Market: Short-Mid Term (2018-2027), Optimistic Scenario (USD Billion)
 
Table 15.30 3D Bioprinting Market: Mid-Long Term (2027-2035), Conservative Scenario (USD Billion)
 
Table 15.31 3D Bioprinting Market: Mid-Long Term (2027-2035), Base Scenario (USD Billion)
 
Table 15.32 3D Bioprinting Market: Mid-Long Term (2027-2035), Optimistic Scenario (USD Billion)
 
Table 15.33 3D Bioprinting Market: Distribution by Applications 2020, 2029 and 2035., Conservative Scenario (USD Billion)
 
Table 15.34 3D Bioprinting Market: Distribution by Applications, 2020, 2029 and 2035, Base Scenario (USD Billion)
 
Table 15.35 3D Bioprinting Market: Distribution by Applications 2020, 2029 and 2035, Optimistic Scenario (USD Billion)
 
Table 15.36 3D Bioprinting Market for Drug Testing / Drug Screening: Short-Mid Term (2018-2027), Conservative Scenario (USD Billion)
 
Table 15.37 3D Bioprinting Market for Drug Testing / Drug Screening: Short-Mid Term (2018-2027), Base Scenario (USD Billion)
 
Table 15.38 3D Bioprinting Market for Drug Testing / Drug Screening: Short-Mid Term (2018-2027), Optimistic Scenario (USD Billion)
 
Table 15.39 3D Bioprinting Market for Drug Testing / Drug Screening: Mid-Long Term (2027-2035), Conservative Scenario (USD Billion)
 
Table 15.40 3D Bioprinting Market for Drug Testing / Drug Screening: Mid-Long Term (2027-2035), Base Scenario (USD Billion)
 
Table 15.41 3D Bioprinting Market for Drug Testing / Drug Screening: Mid-Long Term (2027-2035), Optimistic Scenario (USD Billion)
 
Table 15.42 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Short-Mid Term (Till 2027), Conservative Scenario (USD Billion)
 
Table 15.43 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Short-Mid Term (Till 2027), Base Scenario (USD Billion)
 
Table 15.44 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Short-Mid Term (Till 2027), Optimistic Scenario (USD Billion)
 
Table 15.45 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Mid-Long Term (2027-2035), Conservative Scenario (USD Billion)
 
Table 15.46 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Mid-Long Term (2027-2035), Base Scenario (USD Billion)
 
Table 15.47 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Mid-Long Term (2027-2035), Optimistic Scenario (USD Billion)
 
Table 15.48 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Distribution by Tissue Type, 2025, 2030 and 2035, Conservative Scenario (USD Billion)
 
Table 15.49 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Distribution by Tissue Type, 2025, 2030 and 2035, Base Scenario (USD Billion)
 
Table 15.50 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Distribution by Tissue Type, 2025, 2030 and 2035, Optimistic Scenario (USD Billion)
 
Table 15.51 3D Bioprinting Market for Bioprinted Skin: Short-Mid Term (Till 2027), Conservative Scenario (USD Billion)
 
Table 15.52 3D Bioprinting Market for Bioprinted Skin: Short-Mid Term (Till 2027), Base Scenario (USD Billion)
 
Table 15.53 3D Bioprinting Market for Bioprinted Skin: Short-Mid Term (Till 2027), Optimistic Scenario (USD Billion)
 
Table 15.54 3D Bioprinting Market for Bioprinted Skin: Mid-Long Term, (2027-2035), Conservative Scenario (USD Billion)
 
Table 15.55 3D Bioprinting Market for Bioprinted Skin: Mid-Long Term, (2027-2035), Base Scenario (USD Billion)
 
Table 15.56 3D Bioprinting Market for Bioprinted Skin: Mid-Long Term, (2027-2035), Optimistic Scenario (USD Billion)
 
Table 15.57 3D Bioprinting Market for Bioprinted Cornea: Mid-Long Term (Till 2035), Conservative Scenario (USD Billion)
 
Table 15.58 3D Bioprinting Market for Bioprinted Cornea: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
 
Table 15.59 3D Bioprinting Market for Bioprinted Cornea: Mid-Long Term (Till 2035), Optimistic Scenario (USD Billion)
 
Table 15.60 3D Bioprinting Market for Bioprinted Cartilage: Mid-Long Term (Till 2035), Conservative Scenario (USD Billion)
 
Table 15.61 3D Bioprinting Market for Bioprinted Cartilage: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
 
Table 15.62 3D Bioprinting Market for Bioprinted Cartilage: Mid-Long Term (Till 2035), Optimistic Scenario (USD Billion)
 
Table 15.63 3D Bioprinting Market for Bioprinted Bone: Mid-Long Term (Till 2035), Conservative Scenario (USD Billion)
 
Table 15.64 3D Bioprinting Market for Bioprinted Bone: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
 
Table 15.65 3D Bioprinting Market for Bioprinted Bone: Mid-Long Term (Till 2035), Optimistic Scenario (USD Billion)
 
Table 15.66 3D Bioprinting Market for Bioprinted Blood Vessels: Mid-Long Term (Till 2035), Conservative Scenario (USD Billion)
 
Table 15.67 3D Bioprinting Market for Bioprinted Blood Vessels: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
 
Table 15.68 3D Bioprinting Market for Bioprinted Blood Vessels: Mid-Long Term (Till 2035), Optimistic Scenario (USD Billion)
 
Table 15.69 3D Bioprinting Market for Bioprinted Heart Valves: Mid-Long Term (Till 2035), Conservative Scenario (USD Billion)
 
Table 15.70 3D Bioprinting Market for Bioprinted Heart Valves: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
 
Table 15.71 3D Bioprinting Market for Bioprinted Heart Valves: Mid-Long Term (Till 2035), Optimistic Scenario (USD Billion)
 
Table 15.72 3D Bioprinting Market for Organ Transplants: Mid-Long Term (Till 2035), Conservative Scenario (USD Billion)
 
Table 15.73 3D Bioprinting Market for Organ Transplants: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
 
Table 15.74 3D Bioprinting Market for Organ Transplants: Mid-Long Term (Till 2035), Optimistic Scenario (USD Billion)
 
Table 15.75 3D Bioprinting Market for Bioprinted Breast Implants: Long Term (Till 2035), Conservative Scenario (USD Billion)
 
Table 15.76 3D Bioprinting Market for Bioprinted Breast Implants: Long Term (Till 2035), Base Scenario (USD Billion)
 
Table 15.77 3D Bioprinting Market for Bioprinted Breast Implants: Long Term (Till 2035), Optimistic Scenario (USD Billion)
 
Table 15.78 3D Bioprinting Market for Bioprinted Kidney: Mid-Long Term (Till 2035), Conservative Scenario (USD Billion)
 
Table 15.79 3D Bioprinting Market for Bioprinted Kidney: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
 
Table 15.80 3D Bioprinting Market for Bioprinted Kidney: Mid-Long Term (Till 2035), Optimistic Scenario (USD Billion)
 
Table 15.81 3D Bioprinting Market for Bioprinted Liver: Long Term (Till 2035), Conservative Scenario (USD Billion)
 
Table 15.82 3D Bioprinting Market for Bioprinted Liver: Long Term (Till 2035), Base Scenario (USD Billion)
 
Table 15.83 3D Bioprinting Market for Bioprinted Liver: Long Term (Till 2035), Optimistic Scenario (USD Billion)
 
Table 15.84 3D Bioprinting Market for Bioprinted Heart: Long Term (Till 2035), Conservative Scenario (USD Billion)
 
Table 15.85 3D Bioprinting Market for Bioprinted Heart: Long Term (Till 2035), Base Scenario (USD Billion)
 
Table 15.86 3D Bioprinting Market for Bioprinted Heart: Long Term (Till 2035), Optimistic Scenario (USD Billion)
 
Table 15.87 3D Bioprinting Market: Distribution by Region, 2018-2035, Conservative Scenario (USD Billion)
 
Table 15.88 3D Bioprinting Market: Distribution by Region, 2018-2035, Base Scenario 
(USD Billion)
 
Table 15.89 3D Bioprinting Market: Distribution by Region, 2018-2035, Optimistic Scenario (USD Billion)
 
Table 15.90 3D Bioprinting Market: Distribution by Technology, 2018-2035, Conservative Scenario (USD Billion)
 
Table 15.91 3D Bioprinting Market: Distribution by Technology, 2018-2035, Base Scenario (USD Billion)
 
Table 15.92 3D Bioprinting Market: Distribution by Technology, 2018-2035, Optimistic Scenario (USD Billion)
 
Table 15.93 3D Bioprinting Market: 2018, 2027 and 2035 (USD Billion)
 

 

The following companies and organizations have been mentioned in the report:

 

  1. 3D Bioprinting Solutions
  2. 3D Systems
  3. 3Dynamic Systems
  4. 500 Startups
  5. Accellta
  6. Advanced Solutions
  7. Advanced Solutions Life Sciences
  8. Aether
  9. Albert Ludwig University of Freiburg
  10. AMBER (Advanced Materials and BioEngineering Research)
  11. American Process
  12. Amuza
  13. AO Research Institute Davos (ARI)
  14. Aprecia Pharmaceuticals
  15. Aquitaine Science Transfert
  16. ASI Life Sciences
  17. AxolotlBio
  18. Axolotl Biologix
  19. BASF
  20. Belgorod State University
  21. BellaSeno
  22. Ben Franklin Technology Partners
  23. Bio3D Technologies
  24. BioAdvance
  25. BioBots (Allevi)
  26. BioDan Group
  27. Bioftalmik
  28. Bioink Solutions
  29. BioServe Space Technologies
  30. Bone Therapeutics
  31. Bösing Dental and Implant Solutions
  32. Breakout Labs
  33. Brigham and Women's Hospital
  34. Brunel University London
  35. BTI Biotechnology Institute
  36. Cambridge University Hospitals
  37. Canada Foundation for Innovation (CFI)
  38. Captario
  39. Cardiovascular Innovation Institute (CII)
  40. Carnegie Mellon University
  41. Celgene
  42. Cell Applications
  43. CELLINK
  44. Censo Biotechnologies (previously Roslin Cellab)
  45. Center for Advancement of Science in Space (CASIS)
  46. Center for Gene and Cellular Therapies in the Treatment of Cancer (ONCOGEN) 
  47. Cerhum
  48. Chalmers University of Technology
  49. Children’s National Health System
  50. China Resources (Holdings)
  51. Chinese Academy of Engineering
  52. Chungnam National University Hospital
  53. Citizens Bank
  54. Clemson University
  55. Cold Springs Harbor Laboratory
  56. Collagen Solutions
  57. Columbia University
  58. Competence Centre TEDD (Tissue Engineering for Drug Development and Substance Testing)
  59. Cornell University
  60. Cosmo Bio
  61. CPA Group
  62. Crain’s Detroit Business
  63. Cyfuse Biomedical
  64. Danske Bank
  65. DBJ Capital
  66. DePuy Synthes Companies
  67. DiethelmKellerSiberHegner (DKSH)
  68. DigiLab
  69. DreamIt
  70. Drexel University
  71. Eli Lilly
  72. Embrapa Genetic Resources and Biotechnology's Laboratory of Nanobiotechnology (LNANO)
  73. EnvisionTEC
  74. EpiBone
  75. ETH Zurich
  76. European Medicines Agency (EMA)
  77. Ewing Marion Kauffman Foundation
  78. Fernández-Vega Foundation
  79. FLENI
  80. Flexadyne
  81. Flipkart
  82. Foley & Lardner LLP
  83. Forschungsinstitut für Leder und Kunststoffbahnen
  84. Foundation for the Fight Against Infantile Neurological Diseases
  85. Founders Alliance
  86. Fraunhofer CMI
  87. Friedrich-Alexander-University of Erlangen-Nürnberg
  88. FUJIFILM Dimatix
  89. FundersClub
  90. GeSiM
  91. Glidewell
  92. GoPrint3D
  93. GreenByte AB
  94. Greiner Bio-One
  95. Hangzhou Electronic Science and Technology University
  96. Hannover Medical School
  97. Hanyang University
  98. Harvard Medical School
  99. Health Resources and Services Administration (HRSA)
  100. Heart Research Institute
  101. Helisys
  102. Helmholtz-Zentrum Dresden-Rossendorf (HZDR)
  103. Heriot-Watt University
  104. Hoffmann-La Roche
  105. Hogeschool Utrecht
  106. Hospital General Universitario Gregorio Marañón
  107. Houston Methodist
  108. Humane Society International
  109. I&L Biosystems
  110. Image Analysis
  111. INVITRO
  112. Indiana University
  113. Indiegogo
  114. INNOTERE
  115. Innovate UK-MoST
  116. INSION
  117. Institute for Drug Safety Sciences
  118. Institute of Burn Research, Southwest Hospital
  119. International Society for Biofabrication (IBSF)
  120. International Space Station
  121. InvestX Capital
  122. Invetech
  123. IQ ARTISIA
  124. Izumi International
  125. JAFCO
  126. Janssen Research and Development
  127. Johns Hopkins University
  128. Johnson & Johnson
  129. Katholieke Universiteit Leuven
  130. Korea Institute of Machinery and Materials (KIMM)
  131. Korean Institute of Science and Technology (KIST)
  132. Labsun
  133. Le Vivier
  134. Life Science Nord group
  135. L'Oréal
  136. Ludwig Maximilian University of Munich
  137. Luxexcel
  138. Maastricht University
  139. Made In Space
  140. MakerBot
  141. MaRS Innovation
  142. Mass Innovation Labs
  143. Massachusetts Institute of Technology (MIT)
  144. Mayo Clinic
  145. McGill University Health Centre
  146. McMaster University
  147. Medical University of South Carolina
  148. Medicrea
  149. MedImmune
  150. MEDPRIN BIOTECH
  151. Med-Tech Innovation
  152. Merck & Co
  153. Merrill Corporation
  154. Metabridge
  155. Methuselah Foundation
  156. microdrop Technologies
  157. MicroFab Technologies
  158. MIDSCI
  159. Mode Diagnostics
  160. Morriston Hospital
  161. Moss Enterprises
  162. Murdoch Children’s Research Institute (MCRI)
  163. MUSC Bioprinting Research Center
  164. My Doctor
  165. n3D Biosciences
  166. Nano Dimension
  167. Nanyang Technological University
  168. NASA
  169. National Cancer Institute
  170. National Center for Advancing Translational Sciences (NCATS)
  171. National Eye Institute (NEI)
  172. National Institutes of Health (NIH)
  173. National Medical Research Radiological Centre of the Ministry of Health of the Russian    Federation
  174. National Research Council-Industry Research Assistance Program (NRC-IRAP)
  175. National Science Foundation (NSF)
  176. National University of Singapore (NUS)
  177. Neatco
  178. NetScientific
  179. Neutec Group
  180. New Ventures BC
  181. Newcastle University
  182. News/Talk 760 WJR
  183. NextGene Biosystem
  184. Nike
  185. Nippon Venture Capital
  186. Northeastern University
  187. Northwestern University
  188. Novartis
  189. nScrypt
  190. NSF Frontiers in Integrative Biological Research
  191. NSF SBIR
  192. Objet Geometries
  193. Ohio State University
  194. OHSU Knight Cancer Institute
  195. Oregon Health & Science University (OHSU)
  196. Organovo
  197. Ortho Baltic Group
  198. Ourobotics
  199. Oxford MEStar
  200. OxSyBio
  201. Pandorum Technologies
  202. Pennsylvania State University
  203. PeptiGelDesign Technologies
  204. Phonak
  205. Plum Alley Investments
  206. Poietis
  207. Praxis Pharmaceutical
  208. Precise Bio
  209. Pressure BioSciences
  210. Princeton University
  211. ProtoSpace Foundation
  212. Qingdao Unique Products Develop
  213. Queensland University of Technology
  214. Rainbow Biosciences
  215. Range of Motion Project (ROMP)
  216. RBC Royal Bank
  217. REGEMAT 3D
  218. regenHU
  219. Regenovo Biotechnology (subsidiary of Shining3D)
  220. ReproCELL Group
  221. RESAAS Services
  222. Research Centre for Energy, Environment and Technology (CIEMAT)
  223. Rice University
  224. Ricoh
  225. Roche
  226. Rokit
  227. RoosterBio
  228. Royan Institute
  229. R-Pharm
  230. Russian Medical Academy of Postgraduate Education Studies
  231. Sahlgrenska Academy
  232. Samsara Sciences
  233. Sanford Consortium for Regenerative Medicine
  234. Sanitas International
  235. SAP America
  236. SBH Sciences
  237. ScanSource
  238. Sciperio
  239. Scripps Clinic
  240. Seoul National University Bundang Hospital
  241. Seoul National University of Science and Technology
  242. Seraph Robotics
  243. Shanghai Jiao Tong University
  244. Shanghai Man Heng Digital Technology
  245. Shapeways
  246. Shibuya Kogyo
  247. Sichuan Revotek
  248. Siemens
  249. Silentys (Zeltia Group)
  250. Sirris
  251. Skinprint
  252. Skolkovo Innovation Centre
  253. Solidscape
  254. Somos
  255. South by Southwest SXSW Accelerator
  256. Spanish National Research Council
  257. SPIRE Bioventures
  258. Stanford University
  259. Stem Cell Network
  260. Stemorgan Therapeutics
  261. SternAegis Ventures
  262. Stratasys
  263. Sunnybrook Health Sciences Centre
  264. SunP Biotech International
  265. Swansea University Medical School
  266. Swiss Center for Electronics and Microtechnology
  267. Symme 3D
  268. Tanner Friedman
  269. Technical University of Munich (TUM)
  270. TeViDo BioDevices
  271. The Finnish Funding Agency for Innovation
  272. The Scripps Research Institute
  273. The Trade & Industry Group of Gothenburg&Co
  274. The University of Virginia
  275. The Welsh Centre for Burns and Plastic Surgery
  276. The Welsh Centre for Printing and Coating
  277. ThermoFisher Scientific
  278. Tiffany & Co
  279. Tissue Engineering and Regenerative Medicine International Society
  280. Trideo
  281. Tsinghua University
  282. Tufts University
  283. UMC Utrecht
  284. UniQuest
  285. United Rocket and Space Corporation
  286. Universidad Carlos III de Madrid
  287. Université catholique de Louvain
  288. University College of London
  289. University of Antwerp
  290. University of Bath
  291. University of Bayreuth
  292. University of Bordeaux
  293. University of British Columbia
  294. University of California
  295. University of Cambridge 
  296. University of Colorado
  297. University of Dayton
  298. University of Eastern Finland
  299. University of Exeter
  300. University of Iowa College of Engineering
  301. University of Liverpool
  302. University of Louisville
  303. University of Manchester
  304. University of Manitoba
  305. University of Maryland
  306. University of Minnesota
  307. University of Missouri
  308. University of North Carolina
  309. University of Nottingham
  310. University of Otago, Christchurch
  311. University of Pennsylvania
  312. University of Pisa
  313. University of Sheffield
  314. University of South Australia (UniSA)
  315. University of South Carolina
  316. University of Southampton
  317. University of Texas at San Antonio (UTSA)
  318. University of Tokyo
  319. University of Tokyo Edge Capital
  320. University of Toronto
  321. University of Victoria
  322. University of Washington
  323. University of Waterloo
  324. University of Wollongong
  325. University of Zurich
  326. University Santiago de Compostela
  327. USFDA
  328. Utrecht3DMedical (University Medical Center Utrecht)
  329. VisualPing
  330. Vivos Dental
  331. Wake Forest Baptist Medical Center
  332. Wake Forest Institute for Regenerative Medicine
  333. Wallenberg Wood Science Center
  334. Watson Research Center
  335. WiSEED
  336. Wyss Institute (Harvard University)
  337. Xanofi
  338. Xilloc
  339. Yale School of Medicine
  340. Yale University
  341. Z Corporation
  342. Zeev Bregman
  343. Zeltia Group
  344. ZenBio
  345. Zurich University of Applied Sciences (ZHAW)
  346. Zyomic Technologies

 

You may also like

Copyright © Roots Analysis. All Rights Reserved.
website security